Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
CLYM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.30 - $11.55
Previous CloseN/A
Volume51.97K
Average Volume (3M)342.45K
Market Cap
$94.89M
Enterprise Value$147.81M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 19, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding67,300,000
10 Day Avg. Volume384,574
30 Day Avg. Volume342,449
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1497.26
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside580.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Climb Bio News
PremiumCompany Announcements
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases
PremiumCompany Announcements
Climb Bio to Host Virtual Investor Event
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityCLYM reported a cash position of approximately $213 million, providing financial runway through 2027.
Pipeline ExpansionCLYM has expanded their B-cell focused pipeline by in-licensing anti-APRIL antibody CLYM116 from China-based Mabworks Biotech.
Bears Say
Market CompetitionThe competitive CD19-targeting space may challenge budo in terms of distinguishing efficacy and safety despite its promising profile.
---
Ownership Overview
8.53% Insiders
3.39% Mutual Funds
63.16% Other Institutional Investors
20.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.30 and its highest was $11.55 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $94.89M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is May 19, 2025 which is in 69 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Nov 12, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.13.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate is -0.15.
How many shares outstanding does Climb Bio have?
Climb Bio has 67,300,000 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.105%.
Which hedge fund is a major shareholder of Climb Bio?
Currently, no hedge funds are holding shares in CLYM
---
Climb Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (580.27% Upside)
$10.00 (580.27% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 612.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.35%
12-Months-Change
Fundamentals
Return on Equity
-42.08%
Trailing 12-Months
Asset Growth
97.10%
Trailing 12-Months
Company Description
Climb Bio
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
---
CLYM Stock 12 Month Forecast
Average Price Target
$10.00
▲(580.27% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Leap Therapeutics
―
Bioxcel Therapeutics
―
Verrica Pharmaceuticals
―
Foghorn Therapeutics
―
ATAI Life Sciences
―
Best Analysts Covering CLYM
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-38.10%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.10% per trade.
---